Selected vfa bio articles in English language
Given the large number of orphan diseases and because of the huge medical need for new therapeutic options especially for people with rare diseases, there is still a very great deal of work to be done in this area. vfa and vfa bio are strongly committed to rigorously promoting the development of new therapies for orphan diseases throughout the value chain.
vfa and vfa bio represent biopharmaceutical companies with proven expertise in research, development and production of biopharmaceuticals – original products and biosimilars. The competition among biopharmaceutical therapy options is an essential element in improving patient care. The use of biosimilars broadens the financial scope for the health care system, which in turn can be utilized for innovation pharmaceuticals.
According to the regulations of the GSAV (Law for More Safety in the Supply of Pharmaceuticals), the Federal Joint Committee (G-BA) will develop guidelines for automatic substitution of biopharmaceuticals in pharmacies without involving doctors. These guidelines should enter into force in August 2022 at the latest. This regulation has been overwhelmingly rejected by doctors, pharmacists, patients, and pharmaceutical companies.
The new Biotech-Report describing the situation of medical biotechnology in Germany is now available. It was provided by Boston Consulting Group for vfa bio. This yearly report is the only one recording all activities within medical biotechnology in Germany – ranging from startup to big companies. In addition to key economic data on medical biotechnology in Germany in 2020, the focus of this year’s report is on progresses for patients through antibody therapies as well as on the production site Germany for biopharmaceuticals.
The highly complex production of biopharmaceuticals is an area where Germany can make out its strengths. In terms of the number of active ingredients produced, Germany is the leader in Europe and ranks second worldwide. This favorable position should not be jeopardized by short-term cost-cutting measures such as those planned for biosimilars with automatic substitution in pharmacies planned as of 2022.
Due to the demographic development and the existing age limit for blood donors, the number of blood donations in Germany is decreasing; in parallel, an increase in the number of blood reserves required is expected. One solution to this problem could be artificial blood as a transfusion substitute.
Never before has the public focus on medical biotechnology companies been as strong as since the beginning of the Covid 19 pandemic. However, medical biotechnology in Germany also plays an important role in medical progress, regardless of the acute pandemic situation.
The new biotech report describing the situation of medical biotechnology in Germany is now available. The focus of this year’s report is on the benefit of biopharmaceuticals for patients with autoimmune diseases.
The new biotech report describing the situation of medical biotechnology in Germany is now available. It was provided by The Boston Consulting Group for vfa bio. This yearly report is the only one recording all activities within medical biotechnology in Germany – ranging from startup to big companies. In addition to key economic data on medical biotechnology in Germany in 2017, the focus of this year’s report is on the production of biopharmaceuticals as well as on the benefit of biopharmaceuticals for patients with metabolic diseases.
The new biotech report describing the situation of medical biotechnology in Germany is now available. It was provided by The Boston Consulting Group for vfa bio. This yearly report is the only one recording all activities within medical biotechnology in Germany – ranging from startup to big companies. In addition to key economic data on medical biotechnology in Germany in 2016, the focus of this year’s report is on oncology.
The new biotech report describing the situation of medical biotechnology in Germany is now available. It was provided by The Boston Consulting Group for vfa bio. This yearly report is the only one recording all activities within medical biotechnology in Germany – ranging from startup to big companies.
A brief summary of the key economic data in medical biotechnology in Germany, a ten-year comparison and seven assumptions on developments, which are likely to shape the biopharmaceutical industry over the course of the next ten years.